Market Snapshot

The Global Digital Therapeutics Market was valued at US$ 5.66 billion in 2023 and is projected to surpass the market size of US$ 36.47 billion by 2032, exhibiting a CAGR of 23.0% during the forecast period of 2024-2032.

The healthcare industry moved fast in recent years when it comes to integrating digital health solutions. This was made possible by a number of factors like new tech, regulatory action and patient expectations. COVID-19 played a major role in pushing the industry toward digital therapeutics as traditional methods had to stop. Both patients and doctors needed help as they sought effective ways to manage their health remotely. The results were great; from continuous personalized care, better engagement with patients and even better health outcomes, there's no denying that digital health is worth it. And because of all this, regulatory bodies are easing up on getting these technologies approved for mass use. The reason being that they see its potential in helping them solve some pressing healthcare challenges. That’s why we're seeing so much investment pours into the market after such growth in just a few short years.

Key Findings in the Global Digital Therapeutics Market 

• The market surpassed countless traditional healthcare sectors recently. This exhibits an increase in confidence for Digital therapeutics’ potential to revolutionize how we deliver and manage healthcare.
• Favorable regulatory milestones helped catalyze growth of the digital therapeutics.
• FDA approved over 25 Digital therapeutics solutions for different health conditions.
• More than 150 trials are actively exploring efficacy and safety across a ton of medical scenarios to ensure clinical validation remains at the center of things.
• There has also been an influx in investment with venture capital funding soaring above $1.6 billion in 2022 alone which shows that investors have high hopes for digital therapeutics’ future.

To Get more Insights,  Request A Free Sample 

Market Dynamics 

Driver: High Prevalence of Chronic Diseases and the Demand for Digital Therapeutics

One prominent factor driving the global demand for digital therapeutics market is the dramatic rise in chronic diseases. The escalating prevalence of conditions such as diabetes, cardiovascular diseases, and mental health disorders has created an urgent need for innovative and scalable treatment solutions. Digital therapeutics, offering evidence-based therapeutic interventions delivered through digital platforms, are at the forefront of addressing this challenge. The World Health Organization reports that non-communicable diseases (NCDs), primarily chronic diseases, account for 71% of all global deaths annually. Specifically, cardiovascular diseases are the leading cause of death worldwide, claiming 17.9 million lives each year. Diabetes prevalence has also soared, with an estimated 422 million people living with the condition globally, reflecting an increase from 108 million in 1980. Mental health conditions are not far behind, affecting 264 million individuals globally with depression alone.

The burden of chronic diseases extends beyond health implications. Thus, flourishing demand for digital therapeutics market. It also poses a significant economic challenge. The global economic impact of diabetes is estimated at $1.3 trillion, or 1.8% of the global gross domestic product (GDP). Similarly, mental health conditions are projected to drain $16 trillion from the global economy by 2030. These figures highlight not only the scale of the health crisis but also the economic imperative to find effective treatment strategies. Digital therapeutics emerge as a powerful solution in this context. By leveraging technology, they can provide personalized treatment, improve patient engagement, and reduce healthcare costs. Adoption has been further accelerated by COVID-19 which highlighted how important remote care services were needed. A report by Astute Analytica, predicts that by 2025, digital therapeutics will have increased from having just over 34 million users to more than double.

Challenge: Clearing Regulatory and Reimbursement Pathways

While progress has been made across regions, establishing clear regulations in the digital therapeutics market still remains a big challenge for investors… especially since not all are equal enough for support yet. To establish clarity, countries like America and Germany have been pushing forward together to streamline any complex processes that could arise later down the line. Alongside this push comes Germany’s Digital Healthcare Act, which introduces a 'Fast-Track Process'. Its main goal is to make sure Digital therapeutics can get reimbursed without any issues down the road… since all this work means nothing if people can’t afford it at scale if they were only using push us back later on. In addition, the reimbursement landscape for Digital therapeutics is complex, with different policies and criteria for coverage among insurers and healthcare systems. Overcoming this barrier is key to ensuring the accessibility of Digital therapeutics and fostering broad adoption.

Restrain: Rapid Proliferation of Smartphones in Digital Therapeutics Market Making Them Easy Target for Cybercriminal 

More than 92% of the U.S. population had a smartphone at home in 2023, up from less than 25% in 2011. The rapid proliferation of smartphones has revolutionized how we access healthcare services by offering us a gateway to health information, telemedicine consultations and health management apps that all fit into our pockets. Their ubiquity and computing power also make smartphones an essential tool in delivering Digital therapeutics solutions, allowing patients to manage their conditions from anywhere. Today, digital therapeutics apps can be used to monitor health metrics or send reminders about when to take medications — or they can even deliver cognitive behavioral therapy for mental health support. These tools turn personal health management into a daily integrated experience rather than one you remember only during annual visits.

Wherein, cybersecurity emerges as a critical concern in the digital therapeutics market landscape— especially as healthcare data becomes more digitized and connected. The integration of Digital therapeutics poses new vulnerabilities into existing systems that must be protected because cyber criminals are always looking for new entry points to healthcare networks. Cybersecurity involves protecting patient information from unauthorized access while maintaining the confidentiality of health data as it moves through channels. It also encompasses safeguarding infrastructure by implementing measures that prevent unauthorized tampering or destruction of software components running on devices which could be used maliciously.

With patients and healthcare providers entrusting digital therapeutics platforms with their health data and sensitive information, robust cybersecurity measures are also needed to maintain trust and protect against accidental damage that could result from cyber threats.

Segmental Analysis

By Application

Application-wise, treatment dominates the digital therapeutics market with over 72% market share, and this makes sense. Digital therapeutics play a major role in managing and treating chronic conditions, mental health disorders, and all sorts of lifestyle-related diseases. Personalized evidence-based interventions are provided by this segment to address the growing demand for accessible health solutions that can be remotely delivered in a cost-effective way. This helps enhance patient outcomes while lessening the burden on traditional healthcare systems.

The smaller preventive segment is expected to experience rapid growth at a CAGR of 24.2% in the years to come. A signal that healthcare focus is transitioning towards proactive management by curbing chronic illness incidence to cut long-term costs. Engaging interventions designed for healthy behavior promotion, risk factor monitoring, and early warnings for health issues are offered by digital therapeutics in this section.

By Sales channel

B2B sales take up 76.6% of the digital therapeutics market as they offer providers, payers, and employers exactly what they want. Solutions that can easily integrate into broader health programs can be offered to patients as part of comprehensive care packages. The B2B model aligns Digital therapeutics solutions with existing infrastructures allowing streamlined implementation which includes data management and reimbursement processes.

On another note, B2C has the lowest percentage currently but also comes with the highest projected growth rate of 24.3%. Driven by increasing consumer health awareness as well as features that allow users to manage their personal health directly from their phones.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis

North America currently holds more than a 38% market share when it comes to digital therapeutics market. Quite understandable as they have significant investments in both tech and innovation alongside an environment favorable enough for digital growth when it comes to health.

Asia Pacific on the other hand is experiencing rapid expansion with a projection of a CAGR at around 26.2%. This increase is fueled by increasing digitization levels when it comes to healthcare alongside rising disease prevalence and awareness about preventive healthcare. Countries such as Japan, South Korea, and Australia are leading the way with adoption thanks to government initiatives that support digital health technologies. With more people entering the middle class, the internet becoming even more available, and phones being made by everyone, there’s a huge demand for personalized and accessible healthcare. Countries like China and India are leading the way in the digital therapeutics market; this is being used so they can address health issues that have become widespread in crowded areas where normal healthcare services aren’t enough. The governments of these countries are also getting with it. They’re realizing that telehealth and other platforms can make healthcare better overall. The Asia Pacific region is diverse and consistently growing. It’ll be easy to reinvent healthcare here since there’s so much potential to do so.

List of Key Companies Profiled:

• 2MORROW, Inc.
• Akili Interactive Labs, Inc.
• Click Therapeutics, Inc.
• Fitbit, Inc. (Twine Health, Inc.)
• Happify, Inc.
• Kaia Health
• Livongo Health, Inc.
• Medtronic Plc.
• Omada Health, Inc.
• Pear Therapeutics, Inc.
• Proteus Digital Health, Inc.
• Resmed, Inc. (Propeller Health)
• Voluntis, Inc.
• Welldoc, Inc.
• Other Prominent Players

Market Segmentation Overview 

Following are the different segments of the Global Digital Therapeutics (DTx) Market:

By Component:

• Hardware
• Software
• Services

By Application:

• Preventive Applications
  • Prediabetes​
  • Obesity​
  • Nutrition​
  • Lifestyle Management​
  • Others​
• Treatment/Care-related Applications​
  • Diabetes​
  • CNS Disorders​
  • Mental Health Disorder
  • Other CNS Disorders​
  • Chronic Respiratory Disorders​
  • Musculoskeletal Disorders​
  • Cardiovascular Diseases
  • Smoking Cessation​
  • Medication Adherence​
  • Gastrointestinal Disorders​
  • Substance Use & Addiction Management​
  • Rehabilitation & Patient Care​

 By Sales Channel:

• Business-to-business (B2B)
  • Employer
  • Healthcare Provider
  • Payers
  • Pharmaceutical Companies
  • Others
• Business-to-consumer (B2C)
  • Patient
  • Caregiver

By Region:

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America